hong zhang

Mr. hong zhang

Chest Hospital, Tianjin University
+1
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2022 in Cancer Control
Verified
Journal Article
Open access
ZFZhenxing Feng
Zhenxing Feng
YYYan Yin
Yan Yin
BLBin Liu
Bin Liu
YZYafang Zheng
Yafang Zheng
DSDongsheng Shi
Dongsheng Shi
JQJianwen Qin
Jianwen Qin
Background: The FAT atypical cadherin 1/2/3/4 (FAT1/2/3/4) has been linked to the occurrence and development of various cancers. However, the prognostic and immunological role of FAT1/2/3/4 in non-small cell lung cancer (NSCLC) has not been clarified. Methods: The association of FAT1/2/3/4 mutations with tumor mutation burden (TMB), tumor immunity in the microenvironment, and response to ICIs in NSCLC was investigated. Whole-exome sequencing data of lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) samples from the Cancer Genome Atlas (TCGA), and an immunotherapy data set comprising mutation and survival data of 75 NSCLC patients were analyzed. Two independent pan-cancer cohorts with large samples were used to validate the prognostic value of FAT1/2/3/4 mutations in immunotherapy. Results: A high mutation rate of FAT1/2/3/4 (57.3%, 603/1052) was observed in NSCLC patients. TMB was significantly higher in samples with mutated FAT1/2/3/4 compared to samples with wildtype FAT1/2/3/4 ( P < .05). FAT2 mutation was found to be an independent prognostic biomarker in LUAD. FAT1/2/3/4 were aberrantly expressed in LUAD and LUSC, and high FAT2 expression strongly correlated with high PD-L1 levels in LUAD. Moreover, LUAD patients with FAT1 mutations showed significantly high activated dendritic cells infiltration, whereas those with FAT2/3/4 mutations had high infiltration of CD8+ T-cells, M1 macrophages, activated memory CD4+ T-cells, and helper follicular T-cells. It was also observed that FAT1/2/4 mutations were significantly associated with better enhanced objective response and durable clinical benefit, whereas FAT1/2/3 mutations correlated with longer progression-free survival in ICI-treated NSCLC cohort. FAT1/4 mutations were related to better overall survival in pan-cancer patients treated with ICIs. Conclusions: FAT family genes are potential prognostic and immunological biomarkers and correlate with response to ICIs in NSCLC.

1 March 2006 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
SKSatoru Kawai
Satoru Kawai
EIEiji Ikeda
Eiji Ikeda
MSMunehiro Sugiyama
Munehiro Sugiyama
JMJun Matsumoto
Jun Matsumoto
THTetsuya Higuchi
Tetsuya Higuchi
MSMamoru Suzuki
Mamoru Suzuki
In the current study, to elucidate the clinical features of severe malaria, we performed whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) of Plasmodium coatneyi–infected acute-phase Japanese macaques. The infected monkeys clearly exhibited increase in splenic FDG uptake indicating marked enhancement of glucose metabolism. The standardized uptake values (SUVs) of the spleen in the infected monkeys were significantly higher than those in the uninfected monkey. At autopsy, splenomegaly was clearly present in all infected monkeys, and histopathologic findings included hyperplasia of lymphoid follicles in white pulp, a large number of activated macrophage, and congestion of parasitized red blood cells (PRBCs) and malaria pigments in red pulp. We suggest that increase in splenic glucose uptake may thus be closely related to activation of splenic clearance system against blood-stage malarial parasites.

1 April 2022 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
YGYufan Gao
Yufan Gao
MHMinghui Hua
Minghui Hua
JLJun Lv
Jun Lv
YMYanhe Ma
Yanhe Ma
YLYanzhen Liu
Yanzhen Liu
HZhong zhang
hong zhang
Reproducibility of radiomic features of pulmonary nodules between low-dose CT and conventional-dose CT Yufan Gao, Minghui Hua, Jun Lv, Yanhe Ma, Yanzhen Liu, Min Ren, Yaohua Tian, Ximing Li, Hong Zhang

1 June 2023 in Radiology
Verified
Journal Article
Closed access
JZJia Zhou
Jia Zhou
CLChunjie Li
Chunjie Li
HZhong zhang
hong zhang
CLChang Liu
Chang Liu
JYJunjie Yang
Junjie Yang
YCYundai Chen
Yundai Chen
Background Coronary Artery Disease Reporting and Data System (CAD-RADS) was developed to standardize and optimize disease management in patients after coronary CT angiography (CCTA), but the impact of CAD-RADS management recommendations on clinical outcomes remains unclear. Purpose To retrospectively assess the association between the appropriateness of post-CCTA management according to CAD-RADS version 2.0 and clinical outcomes. Materials and Methods From January 2016 to January 2018, consecutive participants with stable chest pain referred for CCTA were prospectively included in a Chinese registry and followed for 4 years. Retrospectively, CAD-RADS 2.0 classification and the appropriateness of post-CCTA management were determined. Propensity score matching (PSM) was used to adjust for confounding variables. Hazard ratios (HRs) for a major adverse cardiovascular event (MACE), relative risks for invasive coronary angiography (ICA), and the corresponding number needed to treat were estimated. Results Of the 14 232 included participants (mean age, 61 years ± 13 [SD]; 8852 male), 2330, 2756, and 2614 were retrospectively categorized in CAD-RADS 1, 2, and 3, respectively. Only 26% of participants with CAD-RADS 1-2 disease and 20% with CAD-RADS 3 received appropriate post-CCTA management. After PSM, appropriate post-CCTA management was associated with lower risk of MACEs (HR, 0.34; 95% CI: 0.22, 0.51; P < .001), corresponding to a number needed to treat of 21 in CAD-RADS 1-2 but not CAD-RADS 3 (HR, 0.86; 95% CI: 0.49, 1.85; P = .42). Appropriate post-CCTA management was associated with decreased use of ICA in CAD-RADS 1-2 (relative risk, 0.40; 95% CI: 0.29, 0.55; P < .001) and 3 (relative risk, 0.33; 95% CI: 0.28, 0.39; P < .001), resulting in a number needed to treat of 14 and 2, respectively. Conclusion In this retrospective secondary analysis, appropriate disease management after CCTA according to CAD-RADS 2.0 was associated with lower risk of MACEs and more prudent use of ICA. ClinicalTrials.gov registration no. NCT04691037 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Leipsic and Tzimas in this issue.

1 August 2020 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
Tuan PhamTuan Pham
Tuan Pham
CFChuanwen Fan
Chuanwen Fan
HZhong zhang
hong zhang
XSXiao-Feng Sun
Xiao-Feng Sun
Click on the article title to read more.

1 June 2023 in Academic Radiology
Verified
Journal Article
Closed access
KCKeyi Cui
Keyi Cui
SLShuo Liang
Shuo Liang
MHMinghui Hua
Minghui Hua
YGYufan Gao
Yufan Gao
ZFZhenxing Feng
Zhenxing Feng
HZhong zhang
hong zhang